News

Elixir Medical announced four-year results from the large 445-patient BIOADAPTOR Randomized Controlled Trial (RCT), comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent (DES) at 34 centers presented at a late-breaking clinical trial session during EuroPCR 2026.

Elixir Medical announced results from the MY-IVL Study at the TCT Conference 2025 that demonstrate performance of Lithix™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in treating heart disease.

Elixir Medical announces key commercial milestone with LithiX™ HC-IVL, a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques. New clinical study to be presented at TCT Conference 2025.

Late-breaking data demonstrate sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) and significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with DynamX® compared to DES.

Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an energy source. IVL technology expands company’s innovative product portfolio.

Elixir Medical’s LithiX HC-IVL system data demonstrate sustained safety and efficacy at six months, as reported at the TCT conference.

Elixir Medical’s LithiX HC-IVL system data demonstrate sustained safety and efficacy at six months, as reported at the TCT conference.

—Late-breaking 12-month data from INFINITY-SWEDEHEART presented at TCT 2024 further validate bioadaptor’s unique mechanism of action in complex PCI population subsets— —Results of INFINITY-SWEDEHEART trial

Late-breaking INFINITY-SWEDEHEART Randomized Clinical Trial (RCT) data evaluating DynamX® Coronary Bioadaptor System’s unique mechanism of action among patients with Acute Coronary Syndrome (ACS) and complex lesion subsets.